| INTRODUCTION
Primary biliary cholangitis (formerly called primary biliary cirrhosis, PBC) is a chronic cholestatic liver disease, characterised by progressive intrahepatic bile duct destruction which may eventually lead to fibrosis, cirrhosis, and death. 1 In the 20 years following the first human liver transplantation in 1963, PBC was the leading indication for liver transplantation in Europe, accounting for 30%-50% of all liver transplantations. 2 However, despite increasing disease prevalence, 3, 4 PBC is no longer a leading indication for liver transplantation. The recent change in nomenclature is figurative for the changed prognosis of patients over the past decades. 5 Today, patients are usually diagnosed with PBC at an early stage, which allows for timely onset of therapy, often resulting in improvement of biochemical parameters and prognosis. [6] [7] [8] [9] [10] [11] [12] However, patients who respond incompletely still have a significantly impaired prognosis compared to an age-and sex-matched general population. 13, 14 In case of liver failure, liver transplantation remains the only therapeutic option to prevent premature death. However, changes in selection criteria for liver transplantation and in the epidemiology, as well as the introduction of ursodeoxycholic acid (UDCA) as an effective treatment, may have impacted the relative importance of PBC as indication for transplantation. Previous European studies that have assessed trends in liver transplantation for PBC reported a decrease in transplantations. However, these studies were either single centre or single-country studies, often covered relatively short study periods, or are now outdated. [15] [16] [17] A long-term European-wide study is currently lacking, as is data on possible changes over time in the characteristics of the subgroup of patients with PBC who still require liver transplantation.
Thus, the primary aim of this study was to assess the time trends in the number of liver transplantations for PBC across Europe over the past three decades, both in absolute and proportional measures. Secondly, we aimed to evaluate the potential changes in characteristics of patients with PBC undergoing liver transplantation during this time period.
| MATERIALS AND METHODS

| Study design
Patient data were obtained through the European Liver Transplantation Registry (ELTR). ELTR data are available to all the members of the European Liver and Intestine Transplant Association (ELITA) for research purposes, once the study protocol is approved. All patients transplanted in ELTR-associated centres from 1 January 1986 until 31 December 2015, were assessed. Patients who underwent combined organ transplantation and patients aged under 18 years at the time of liver transplantation were excluded. In order to more thoroughly assess patients' characteristics, all patients with PBC who were listed for liver transplantation at any of the three liver transplantation centres in the Netherlands during the study period were included for in-depth analyses.
This study was conducted in accordance with the principles of 
| Primary Indications for liver transplantationchanges in absolute and proportional numbers
In 1986 proportion of patients between 40-49 and 50-59 years decreased from 27% and 42% in the first decade, to 21% and 36% respectively in the last decade (both P < 0.001).
| Gender
A total of 761 (12.6%) male and 5267 (87.4%) female patients with PBC were transplanted, corresponding to a male to female ratio of 1:6.9. For non-PBC aetiologies, 74 484 (69.7%) males and 32 348 (30.3%) females underwent transplantation, corresponding to a female to male ratio of 1:0.43. In PBC patients, the proportion of transplantations for males increased significantly from 11.0% in the first decade to 15.1% in the third decade (P < 0.001) ( Figure 5 ). In the first decade, males were significantly older than females with a median age of 56 years (IQR 49-61) and 55 years (IQR 48-60) respectively (P < 0.05), but no differences were found in the second (P = 0.755) and third decades (P = 0.695) ( Figure S1A ).
| MELD scores
In patients with PBC, the median MELD score at time of transplanta- Year of transplantation 1 9 8 6 1 9 8 7 1 9 8 8 1 9 8 9 1 9 9 0 1 9 9 1 1 9 9 2 1 9 9 3 1 9 9 4 1 9 9 5 1 9 9 6 1 9 9 7 1 9 9 8 1 9 and 2015, corresponding with a waiting list mortality of 12%, 16%, and 33% in the consecutive decades. In addition, three (1.6%) patients were removed at personal request or due to improved condition. The remaining 151 (82.1%) were transplanted.
| Study population
Characteristics and biochemistry of the 151 patients who were transplanted for PBC in the Netherlands are presented in Table S1 .
The median age at the time of transplantation was 54 years (IQR 48-59). Transplanted patients were diagnosed with PBC at a med- 
| Primary indications for liver transplantation:
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| UDCA treatment and response for all patients with PBC
A total of 102 (67.5%) transplanted patients were treated with UDCA at the time of listing. The proportion of patients who were treated with UDCA increased significantly over time, from 37% in the first, to 92% in the last decade (P < 0.001). Table 2 shows the biochemical response for these UDCA-treated patients according to the Barcelona, Paris I, and GLOBE response criteria. 14, 20, 24, 25 In this cohort of transplanted patients with PBC, 6-47% of patients showed a biochemical response to treatment, depending on the response criteria. The Paris I criteria identified the lowest percentage of complete biochemical responders after 12 months of UDCA treatment (6%). When classification by different response criteria was compared, this proportion was significantly lower than the percentage of complete responders as classified by the Barcelona criteria (30%) (P = 0.008) and by the GLOBE criteria (28%) (P = 0.004).
| DISCUSSION
This study represents the largest European-wide study on time ago. However, differences over time were quantitatively small.
The current study is the first to demonstrate a stable annual absolute number of transplantations for PBC over the past 10 years in Europe. This result confirms that today, in a minority of patients, we are still unable to prevent liver failure which underlines the necessity of additional therapeutic options for this group. A study by
Lee et al that assessed transplantations trends for PBC in the United
States showed an absolute annual decrease without reaching a steady state, but their study period only covered 11 years and ended in 2006. 13 Our finding seems in contrast to the recent study by
Webb et al reporting a decrease in the United Kingdom and the United States up until 2014. However, a true comparison is difficult, since the latter study only reported listings for transplantation and not actual liver transplantation, and measured numbers as a ratio against the total (increasing) general population. However, the steady absolute number of transplantations for PBC is also discordant with an overall increase in overall numbers of annual transplantations and with the increasing prevalence of PBC over the past decades. 3, 4 Therefore, the stable absolute number of transplantations for PBC that we report could possibly be interpreted as a relative decrease. 9 8 6 1 9 8 7 1 9 8 8 1 9 8 9 1 9 9 0 1 9 9 1 1 9 9 2 1 9 9 3 1 9 9 4 1 9 9 5 1 9 9 6 1 9 9 7 1 9 9 8 1 9 9 9 2 0 0 0 PBC patients, which was higher than for most other aetiologies. We also identified several changes in the characteristics of patients undergoing transplantation for PBC over the past three decades. We found an increase in age at time of transplantation. This was in line with the results from a long-term study from Birmingham and a recent larger study covering both the UK and the USA. 16, 27 Most noticeable, however, was our finding of an increasing proportion of patients with PBC transplanted at age >60 years. This may be related to an overall improved medical care and physical condition, permitting transplantation at higher ages. The influence of possible changes in environmental triggers involved in the development of PBC should also be considered, especially since a recent large study showed that the age at PBC diagnosis has markedly increased over the years. 28 However, with a median age at diagnosis of 46 years in patients with PBC listed for transplantation within our in-depth population, this population undergoing liver transplantation for PBC was much younger at diagnosis than the large overall cohorts reported by the Global PBC Study Group (55 years) and the UK-PBC Study Group (55 years). 21, 29 This suggests that young patients may be more likely to develop endstage disease requiring liver transplantation, as has previously been reported. 30 Furthermore, we found that an increasing number of males were transplanted for PBC over time, which was also reported in the United States. 27 The increasing male to female ratio reported in To the best of our knowledge, our study was the first to assess time trends in liver transplantation for PBC throughout Europe over a sizeable period of 30 years, during which UDCA was introduced as the standard of care. We were able to include all liver transplantations reported to the ELTR, resulting in a large population of 6029 transplanted PBC patients. The additional nationwide in-depth analysis over the same study period enabled us to characterise the population in need for liver transplantation more extensively over time. However, some limitations should be taken into account. Biochemical data were incomplete in both the ELTR data and the Dutch in-depth analysis.
However, due to the large population and the similar patterns found in both analyses, we believe this has not introduced an important bias.
Second, our in-depth analyses are based on data of Dutch patients only and the extent to which findings can be generalised is uncertain.
Nevertheless, since patient characteristics and MELD scores at transplantation were comparable to the PBC population in the ELTR database and similar transplantation patterns over time were observed, the results of our nationwide in-depth analyses may well be representative of the European PBC population in need of liver transplantation.
In conclusion, we found that, despite a relative decrease, the absolute number of transplantations for PBC has reached a steady state. Still, over 200 European patients with PBC undergo liver transplantation annually. These patients are slightly older, have higher MELD scores, and are more likely to be male than 30 years ago. Effective second-line therapies may further reduce the need for liver transplantation in patients with PBC in the future.
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